A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
The purpose of this study was to evaluate the efficacy of enzalutamide plus androgen deprivation therapy (ADT) as measured by radiographic progression-free survival (rPFS) based on central review. The study also evaluated the safety of enzalutamide plus ADT in mHSPC.
Epistemonikos ID: 7f0aa17bc9efef5d4810af273f3b0bfb616fda77
First added on: May 12, 2024